Add Yahoo as a preferred source to see more of our stories on Google. Medtronic said Monday it received 510(k) clearance from the Food and Drug Administration for an app to connect its smart insulin ...

Please provide your email address to receive an email when new articles are posted on . The MiniMed Go app received FDA 510(k) clearance for people with type 1 or type 2 diabetes requiring insulin.

NEW YORK — Federal prosecutors said CVS Pharmacy will pay $37.76 million to resolve accusations that the company repeatedly dispensed more insulin to patients than their prescriptions required and ...

Pharmacy chain CVS will pay $37.8 million for dispensing and billing health care plans including the military’s Tricare for more insulin than was prescribed for the pharmacy’s diabetic customers, ...

CVS Pharmacy agreed to pay $37.7 million to settle a lawsuit with the United States over a decade-long practice of over-dispensing insulin to customers and then seeking undue reimbursements from ...

CVS reached a settlement on Tuesday with the U.S. Attorney for the Southern District of New York for over $37.75 million after the retailer was accused of over-dispensing insulin pens to patients.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min According to the DOJ, CVS ...

CVS Pharmacy will pay $37.76 million to resolve allegations that it over-dispensed insulin pens and improperly billed federal health programs over a 10-year period. The settlement resolves claims that ...

CVS has agreed to pay almost $38 million to settle allegations that its pharmacies overcharged the government for insulin pens over a decade, putting to bed a Department of Justice lawsuit and several ...

CVS Health (CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims that it overbilled government healthcare programs for insulin pens. The ...

NEW YORK, Dec 2 (Reuters) - CVS Health (CVS.N), opens new tab will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements ...